Lumos Diagnostics Holdings Limited
ASX:LDX.AX
0.033 (AUD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.383 | 1.383 | 2.724 | 2.724 | 2.544 | 2.544 | 3.214 | 3.214 | 2.601 | 2.601 | 5.224 | 5.224 | 4.204 | 4.204 | 1.721 | 1.533 | 1.196 | 1.151 |
| Cost of Revenue
| 0.666 | 0.666 | 1.042 | 1.042 | 1.367 | 1.367 | 3.477 | 3.477 | 1.401 | 1.401 | 3.268 | 3.268 | 1.859 | 1.859 | 0.997 | 0.889 | 0.654 | 0.63 |
| Gross Profit
| 0.718 | 0.718 | 1.683 | 1.683 | 1.177 | 1.177 | -0.263 | -0.263 | 1.201 | 1.201 | 1.956 | 1.956 | 2.345 | 2.345 | 0.723 | 0.645 | 0.542 | 0.521 |
| Gross Profit Ratio
| 0.519 | 0.519 | 0.618 | 0.618 | 0.463 | 0.463 | -0.082 | -0.082 | 0.462 | 0.462 | 0.374 | 0.374 | 0.558 | 0.558 | 0.42 | 0.42 | 0.453 | 0.453 |
| Reseach & Development Expenses
| 0.055 | 0.055 | 0.001 | 0.001 | 0.129 | 0.129 | 0.518 | 0.518 | 0.146 | 0.146 | 0.289 | 0.289 | 0.331 | 0.331 | 0.653 | 0.582 | 0.386 | 0.371 |
| General & Administrative Expenses
| 1.046 | 1.046 | 0.864 | 0.864 | 1.207 | 1.207 | 1.601 | 1.601 | 2.794 | 2.794 | 2.071 | 2.071 | 2.814 | 2.814 | 3.097 | 2.76 | 1.681 | 1.617 |
| Selling & Marketing Expenses
| 0.025 | 0.025 | 0.154 | 0.154 | 0.087 | 0.087 | 0.57 | 0.57 | 0.565 | 0.565 | 0.028 | 0.028 | 0.489 | 0.489 | 0.49 | 0.437 | 0.425 | 0.409 |
| SG&A
| 2.854 | 2.854 | 2.788 | 2.788 | 2.982 | 2.982 | 6.275 | 6.275 | 5.941 | 5.941 | 5.88 | 5.88 | 3.303 | 3.303 | 3.587 | 3.197 | 2.106 | 2.026 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 3.523 | 3.523 | 1.799 | 1.799 | 4.351 | 4.351 | 16.878 | 16.878 | 6.636 | 6.636 | 6.127 | 6.127 | 3.58 | 3.58 | 3.226 | 2.875 | 2.487 | 2.392 |
| Operating Income
| -2.815 | -2.815 | -1.927 | -1.927 | -2.909 | -2.909 | -8.015 | -8.015 | -5.436 | -5.436 | -4.212 | -4.212 | -1.289 | -1.289 | -3.447 | -3.071 | -1.945 | -1.871 |
| Operating Income Ratio
| -2.035 | -2.035 | -0.707 | -0.707 | -1.144 | -1.144 | -2.494 | -2.494 | -2.09 | -2.09 | -0.806 | -0.806 | -0.307 | -0.307 | -2.003 | -2.003 | -1.626 | -1.626 |
| Total Other Income Expenses Net
| -0.392 | -0.392 | 0.723 | 0.723 | -0.374 | -0.374 | -9.303 | -9.303 | -0.108 | -0.108 | -1.644 | -1.644 | -0.371 | -0.371 | 0.927 | 0.826 | -0.241 | -0.232 |
| Income Before Tax
| -3.207 | -3.207 | -1.204 | -1.204 | -3.282 | -3.282 | -17.318 | -17.318 | -5.544 | -5.544 | -5.856 | -5.856 | -1.66 | -1.66 | -2.519 | -2.245 | -2.186 | -2.103 |
| Income Before Tax Ratio
| -2.319 | -2.319 | -0.442 | -0.442 | -1.29 | -1.29 | -5.388 | -5.388 | -2.131 | -2.131 | -1.121 | -1.121 | -0.395 | -0.395 | -1.464 | -1.464 | -1.828 | -1.828 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.026 | 0 | 0 |
| Net Income
| -3.207 | -3.207 | -1.204 | -1.204 | -3.282 | -3.282 | -17.318 | -17.318 | -5.544 | -5.544 | -5.856 | -5.856 | -1.66 | -1.66 | -2.49 | -2.218 | -2.186 | -2.103 |
| Net Income Ratio
| -2.319 | -2.319 | -0.442 | -0.442 | -1.29 | -1.29 | -5.388 | -5.388 | -2.131 | -2.131 | -1.121 | -1.121 | -0.395 | -0.395 | -1.447 | -1.447 | -1.828 | -1.828 |
| EPS
| -0.007 | -0.007 | -0.005 | -0.005 | -0.016 | -0.016 | -0.11 | -0.11 | -0.037 | -0.037 | 0 | 0 | -0.019 | -0.019 | -0.096 | 0 | 0 | 0 |
| EPS Diluted
| -0.007 | -0.007 | -0.005 | -0.005 | -0.016 | -0.016 | -0.11 | -0.11 | -0.037 | -0.037 | 0 | 0 | -0.019 | -0.019 | -0.096 | 0 | 0 | 0 |
| EBITDA
| -2.191 | -2.191 | -1.636 | -1.395 | -1.934 | -1.934 | -7.947 | -7.947 | -4.887 | -4.887 | -4.2 | -4.2 | -1.146 | -1.146 | -3.37 | -3.043 | -1.913 | -1.84 |
| EBITDA Ratio
| -1.584 | -1.584 | -0.601 | -0.512 | -0.76 | -0.76 | -2.473 | -2.473 | -1.879 | -1.879 | -0.804 | -0.804 | -0.273 | -0.273 | -1.959 | -1.985 | -1.599 | -1.599 |